NCT05635708 2026-03-18
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
Phase 2 Active not recruiting
Clinical Trials
19 trialsNCT05502250 2026-03-06
HOVON164HL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
NCT06356597 2026-02-24
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting
NCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06010303 2025-11-17
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 2 Active not recruiting
NCT06139419 2025-11-17
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05909904 2025-10-07
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
BeiGene
Phase 2 Active not recruiting
NCT06124378 2025-09-24
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
First Affiliated Hospital of Guangxi Medical University
Phase 2 Active not recruiting
NCT05604560 2025-07-23
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Active not recruiting
NCT05319574 2025-06-12
SACTION01
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06009861 2025-06-06
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Peking University Hospital of Stomatology
Phase 2 Active not recruiting
NCT06056804 2025-04-02
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Beijing Friendship Hospital
Phase 2 Active not recruiting
NCT05586061 2025-02-07
RCTS
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
NCT06239532 2024-11-21
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
Qilu Hospital of Shandong University
Phase 2 Active not recruiting
NCT05520619 2024-11-18
EC-CRT-002
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05724329 2024-09-19
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT05519865 2024-08-07
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Chipscreen Biosciences, Ltd.
Phase 2 Active not recruiting
NCT04727996 2024-04-19
BTC-BGB
Seoul National University Hospital
Phase 2 Active not recruiting
NCT04776590 2024-04-12
CRISEC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Active not recruiting